The American Thyroid Association (ATA) developed and published the guidelines online at www.liebertpub.com/thy. "Following careful peer review, this is the first comprehensive set of clinical guidelines for the treatment of all medullary thyroid carcinoma (MTC) disorders," says Charles H. Emerson, Editor-in-Chief of the Journal Thyroid that also published the guidelines.
"These evidence-based guidelines will become a benchmark for patient management and clinical research, as they illuminate the diagnostic and therapeutic strategies required when caring for gravely ill patients and those in the anxiety-ridden early stages of the disease, and when offering testing and counselling to family members."
The ATA has compiled 122 evidence-based recommendations that cover a range of clinical topics, including diagnosis and therapy for early disease, genetic testing, surgical management, post-surgical treatment and monitoring, management of persistent or recurrent MTC and metastatic disease, and long-term follow-up. The guidelines also propose directions for future research on MTC.
MTC is a complex disease that accounts for about four percent of all thyroid cancer cases in the United States, according to the researchers. Nearly 25 percent of cases worldwide are familial and present as an autosomal inherited disorder. In individuals with the inherited form of MTC, a preneoplastic lesion called C-cell hyperplasia will first develop and then progress to an invasive, life-threatening malignancy.
"Medullary thyroid cancer is a rare and fascinating disease that few health care professionals ever master," says Richard T. Kloos, Chair of the ATA Guidelines Task Force. "The ATA guidelines promote optimal medical care that is grounded in an review of the literature by an international and multidisciplinary panel. It is our hope that they will serve all the professionals that care for these patients, including those in the fields of endocrinology, genetics, paediatrics, radiology, nuclear medicine, surgery, and oncology."
MEDICA.de; Source: Mary Ann Liebert, Inc./Genetic Engineering News